Long-term follow-up of microscopic polyangiitis, 17-year experience at a single center

Abstract Background Long-term prognoses of Wegener granulomatosis (WG) and Churg–Strauss syndrome (CSS) are known; however, few data exist on long-term prognoses for microscopic polyangiitis (MPA). Our aim was to analyse the prognoses of MPA. Methods Cohort study with retrospective selection of pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of internal medicine 2010-12, Vol.21 (6), p.542-547
Hauptverfasser: Borao-Cengotita-Bengoa, María, Corral-Gudino, Luis, del Pino-Montes, Javier, Lerma-Márquez, Jose Luis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Long-term prognoses of Wegener granulomatosis (WG) and Churg–Strauss syndrome (CSS) are known; however, few data exist on long-term prognoses for microscopic polyangiitis (MPA). Our aim was to analyse the prognoses of MPA. Methods Cohort study with retrospective selection of patients. Twenty-two patients admitted to our Hospital (1990–2006) with biopsy-proven MPA were studied. The start date for entry into the study was the date of diagnosis. Statistical analysis was performed to look for prognostic factors for survival. Results MPA patients were followed-up for a median of 78 (5–131) months. MPA patients were treated with cyclophosphamide (Cy) plus corticosteroid (Cs) (59%) or Cs alone (41%). Seven MPA patients died. Cumulative MPA patient survival at 1, 5, and 10 years were 85% (75–95%), 85% (75–95%), and 74% (60–88%) in those treated with Cy plus Cs and 50% (32–68%), 36% (14–58%), and 0% (0–30%) in those treated with Cs alone, respectively ( P = 0.04). Disease extent index < 5 ( P = 0.02) and age < 65 years ( P = 0.02) were associated with improved survival rates in MPA patients treated with Cy. Five MPA (23%) patients relapsed after a median of 54 months (35–93). No variables were related to relapses. Despite treatment, 11 MPA (50%) patients developed end-stage renal disease after a median of 9 months (0–53). Conclusions Most MPA patients had life-threatening renal or lung involvement at diagnosis. Patients not treated with immunosuppressants had a poorer prognosis. The long-term prognosis of MPA patients who survived 6 months post diagnosis was good, although renal survival rates are low.
ISSN:0953-6205
1879-0828
DOI:10.1016/j.ejim.2010.09.005